Table 2.
Estimated Effects of Incident Cancer and Education on Memory Function and Annual Rate of Memory Change using Linear Mixed-Effects Models, the US Health and Retirement Study, United States, 1998–2016.
Characteristic | β | Model 1a 95% CI |
P-value |
---|---|---|---|
| |||
Memory function (SD units) and memory change (SD units/decade) in those with 12 years of education | |||
Participants with no cancer during follow-up: | |||
Memory function at age 75 | −0.894 | (−0.937, −0.851) | <0.001 |
Memory slope with linear age (centered at 75) | −1.111 | (−1.140, −1.077) | <0.001 |
Memory slope with quadratic age (SD units /decade2) | −0.298 | (−0.303, −0.293) | <0.001 |
Participants with an incident cancer diagnosis: | |||
Difference in memory score right before cancer diagnosisb | 0.052 | (0.024, 0.080) | <0.001 |
Short-term change in memory following diagnosis | −0.060 | (−0.084, −0.036) | <0.001 |
Difference in memory slope before diagnosisb | 0.047 | (0.021, 0.074) | <0.001 |
Difference in memory slope after diagnosisb | 0.058 | (0.019, 0.098) | 0.004 |
| |||
Effect of one additional year of education on the following estimates: | |||
Participants with no cancer during follow-up: | |||
Memory function at age 75 | 0.050 | (0.045, 0.054) | <0 .001 |
Memory slope with linear age | 0.018 | (0.015, 0.022) | <0.001 |
Participants with an incident cancer diagnosis: | |||
Difference in memory score right before cancer | −0.003 | (−0.010, 0.004) | 0 .361 |
Short-term change in memory following diagnosis | 0.005 | (−0.030, 0.013) | 0.219 |
Difference in memory slope before diagnosis | −0.006 | (−0.014, 0.002) | 0.149 |
Difference in memory slope after diagnosis | 0.002 | (−0.010, 0.014) | 0.711 |
Model adjusted for sex, race, southern birthplace, childhood socioeconomic index, total household wealth, height, body mass index, vigorous physical activity, current and ever smoking, alcohol use, childhood self-rated health, and comorbidities (hypertension, diabetes, heart disease, stroke, lung disease)
Compared to participants with no cancer over the follow-up, as the reference group